BiomX (PHGE) Stock Price, News & Analysis

Company Overview

BiomX Inc., a clinical-stage biopharmaceutical company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic disease. It is developing BX211, a phage therapy, which is in phase 2 clinical study for the treatment of diabetic foot osteomyelitis. The company's product pipeline also includes BX004, a phage therapy for cystic fibrosis patients with chronic pulmonary infections caused by Pseudomonas aeruginosa that is in Phase 1b/2a clinical trials. BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel.

Key Stats

• Today's Range: $0.72 to $0.78
• 50-Day Range: $0.44 to $0.62
• 52-Week Range: $0.40 to $3.86
• Volume: 53,300 shs
• Average Volume: 89,672 shs
• Market Capitalization: $10.44 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $21.00
• Consensus Rating: Buy

PHGE Stock Analysis - Frequently Asked Questions

How have PHGE shares performed this year?

BiomX's stock was trading at $0.7301 at the beginning of the year. Since then, PHGE stock has decreased by 44.0% and is now trading at $0.4090.
View the best growth stocks for 2025 here.

How were BiomX's earnings last quarter?

BiomX Inc. (NYSEMKT:PHGE) announced its earnings results on Monday, May, 15th. The company reported ($2.00) earnings per share for the quarter, missing analysts' consensus estimates of ($1.80) by $0.20.

When did BiomX's stock split?

BiomX's stock reverse split on Monday, August 26th 2024. The 1-10 reverse split was announced on Thursday, August 15th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Friday, August 23rd 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Who are BiomX's major shareholders?

BiomX's top institutional shareholders include Nantahala Capital Management LLC (9.97%), Alyeska Investment Group L.P. (6.36%), AIGH Capital Management LLC (6.27%) and Allostery Investments LP (3.76%). Insiders that own company stock include Israel Biofund Gp Limi Orbimed, Chidozie Ugwumba and Assaf Oron.
View institutional ownership trends.

How do I buy shares of BiomX?

Shares of PHGE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of BiomX own?

Based on aggregate information from My MarketBeat watchlists, some other companies that BiomX investors own include Predictive Oncology (POAI), JPMorgan Chase & Co. (JPM), Abbott Laboratories (ABT), NVIDIA (NVDA), Zomedica (ZOM), Insulet (PODD) and Ford Motor (F).

Company Calendar

• Last Earnings: 5/15/2023
• Today: 6/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSEMKT
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NYSEMKT:PHGE
• CIK: 1739174
• Web: www.biomx.com
• Phone: 972 7 23942377
• Fax: N/A
• Employees: 120
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $21.00
• High Stock Price Target: $21.00
• Low Stock Price Target: $21.00
• Potential Upside/Downside: +4,396.8%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.85)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$28.32 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -127.82%
• Return on Assets: -56.50%

Debt

• Debt-to-Equity Ratio: 0.51
• Current Ratio: 2.84
• Quick Ratio: 2.84

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.70 per share
• Price / Book: 0.67

Miscellaneous

• Outstanding Shares: 26,176,000
• Free Float: 44,044,000
• Market Cap: $12.22 million
• Optionable: Not Optionable
• Beta: 1.43